Varicella Vaccine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Market is Segmented by Vaccine Type (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Application, and Geography

Market Snapshot

varicella live vaccine 1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The varicella vaccine market is expected to register a CAGR of 5.6% during the forecast period. Varicella vaccines contain an attenuated (weakened) live strain of the varicella-zoster (chickenpox) virus. These vaccines stimulate the immune system against the varicella-zoster virus as the infection can cause serious diseases such as herpes zoster and chickenpox. Varicella vaccines are of two types namely monovalent and combination varicella vaccines. The monovalent vaccines contain a single weakened strain of the varicella-zoster virus, however, the combination of varicella vaccines contain multiple strains of infectious agents. These vaccines are used for chickenpox, herpes zoster and mumps, measles, rubella, and varicella immunization. Absence of chickenpox immunization can lead to complications such as bacterial infections of the skin, soft tissues, bones, joints or bloodstream (sepsis), pneumonia, encephalitis, and even death.

As per the study report published in Human Vaccines & Immunotherapeutic 2019, globally annual varicella disease burden is estimated to be 140 million cases, of these 4.2 million cases have severe complications that can lead to hospitalization and death, neonates and the immunocompromised individuals particularly are at high risk.

In addition, according to the Centers for Disease Control and Prevention (CDC), each year in United States approximately 11,000 individuals get hospitalize due to chicken pox complications.

Furthermore, growing awareness regarding varicella vaccines usage, active participation of government in immunization programs and surge in the acceptance of varicella vaccines are the key driving factors in varicella vaccine market.

Scope of the Report

As per the scope of the report, varicella or chickenpox is an acute and highly contagious disease caused by the varicella-zoster virus, which is a member of the herpes family. It usually occurs during childhood and is very contagious. The varicella vaccine market is segmented by vaccine type, application, and geography.

By Vaccine
Monovalent Varicella Vaccine
Combination Varicella Vaccine
By Application
Chickenpox Immunization
Herpes Zoster Immunization
Mumps, Measles, Rubella, and Varicella Immunization
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East & Africa
South Africa
Rest of Middle East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monovalent Varicella Vaccine Segment is Expected to Hold a Significant Market Share in the Varicella Vaccine Market

The monovalent varicella vaccine segment holds a significant market share in varicella vaccine market and is anticipated to show a similar trend over the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children compared to combination vaccines. The monovalent vaccines contain a single strain of a single varicella live vaccines, contain a weakened strain of the varicella-zoster virus. These vaccines are used for chickenpox immunization and herpes zoster immunization. According to the Centers for Disease Control and Prevention (CDC), an estimated one million cases of shingles (Herpes Zoster) occur annually in the United States. In addition, approximately 1 out of 3 people in the United States will develop shingles (Herpes Zoster) during their lifetime. Furthermore, easy availability and high adoption of monovalent products are the key driving factors in the monovalent varicella vaccine segment.

Varicella Live Vaccine key trend 1.png

North America is Expected to Hold a Significant Share in the Market and it is Expected to do the Same during the Forecast Period

The North American region is expected to hold a major market share of the global varicella vaccine market, due to the presence of major players involved in the commercialization and development of vaccines in this region. According to the Centers for Disease Control and Prevention (CDC) estimates, more than 3.5 million cases of varicella, 9,000 hospitalizations, and around 100 deaths are prevented by varicella vaccination each year in the United States. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.

Varicella Live Vaccine Market 2

Competitive Landscape

The varicella vaccine market is consolidated and consists of a few major players. Some of the prominent players operating in the varicella vaccine market are GlaxoSmithKline PLC, Merck & Co. Inc., GC Pharma (Green Cross Holdings), Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, Sanofi, Takeda Pharmaceutical Company Limited, and Mitsubishi Tanabe Pharma Corporation.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness Regarding the Use of Varicella Vaccine

      2. 4.2.2 Increase in Immunization Programs Across the World

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Vaccine

      2. 4.3.2 Time-consuming Process for the Development of Varicella Vaccine

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Vaccine

      1. 5.1.1 Monovalent Varicella Vaccine

      2. 5.1.2 Combination Varicella Vaccine

    2. 5.2 By Application

      1. 5.2.1 Chickenpox Immunization

      2. 5.2.2 Herpes Zoster Immunization

      3. 5.2.3 Mumps, Measles, Rubella, and Varicella Immunization

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 GlaxoSmithKline PLC

      2. 6.1.2 Merck & Co. Inc.

      3. 6.1.3 GC Pharma (Green Cross Holdings)

      4. 6.1.4 Bio-Med Pvt Ltd

      5. 6.1.5 Novo Medi Sciences Pvt Ltd

      6. 6.1.6 Sanofi

      7. 6.1.7 Takeda Pharmaceutical Company Limited

      8. 6.1.8 Mitsubishi Tanabe Pharma Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Varicella Vaccine Market market is studied from 2018 - 2026.

The Varicella Vaccine Market is growing at a CAGR of 5.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

GlaxoSmithKline Plc, Merck & Co., Inc, GC Pharma (Green Cross Holdings), Bio-Med Pvt. Limited, Novo Medi Sciences Pvt. Ltd are the major companies operating in Varicella Vaccine Market .

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!